You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Harvard Business School
Boehringer Ingelheim
Medtronic
Merck

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

PRINZIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Prinzide, and what generic alternatives are available?

Prinzide is a drug marketed by Merck and is included in one NDA.

The generic ingredient in PRINZIDE is hydrochlorothiazide; lisinopril. There are thirty-two drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; lisinopril profile page.

Summary for PRINZIDE
Drug patent expirations by year for PRINZIDE
Recent Clinical Trials for PRINZIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Centre Hospitalier Universitaire de Saint EtiennePhase 4

See all PRINZIDE clinical trials

US Patents and Regulatory Information for PRINZIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck PRINZIDE hydrochlorothiazide; lisinopril TABLET;ORAL 019778-003 Nov 18, 1993 DISCN Yes No   Start Trial   Start Trial   Start Trial
Merck PRINZIDE hydrochlorothiazide; lisinopril TABLET;ORAL 019778-001 Feb 16, 1989 DISCN Yes No   Start Trial   Start Trial   Start Trial
Merck PRINZIDE hydrochlorothiazide; lisinopril TABLET;ORAL 019778-002 Feb 16, 1989 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PRINZIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck PRINZIDE hydrochlorothiazide; lisinopril TABLET;ORAL 019778-002 Feb 16, 1989   Start Trial   Start Trial
Merck PRINZIDE hydrochlorothiazide; lisinopril TABLET;ORAL 019778-003 Nov 18, 1993   Start Trial   Start Trial
Merck PRINZIDE hydrochlorothiazide; lisinopril TABLET;ORAL 019778-001 Feb 16, 1989   Start Trial   Start Trial
Merck PRINZIDE hydrochlorothiazide; lisinopril TABLET;ORAL 019778-003 Nov 18, 1993   Start Trial   Start Trial
Merck PRINZIDE hydrochlorothiazide; lisinopril TABLET;ORAL 019778-001 Feb 16, 1989   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for PRINZIDE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0454511 99C0009 Belgium   Start Trial PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0443983 C00443983/03 Switzerland   Start Trial PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
0565634 06C0030 France   Start Trial PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0503785 CA 2011 00026 Denmark   Start Trial PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0502314 C300095 Netherlands   Start Trial PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Harvard Business School
McKinsey
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.